Blood Purification · 2021 · 24 citations · 15 references
PharmacyPharmacokineticsPharmacologyHemodialysisRenal PharmacokineticsRenal Replacement TherapyHeart FailureHeart Failure PharmacotherapyPharmacokinetics In Renal ImpairmentRenal PharmacologyRenal Replacement Therapy PharmacologyB-type Natriuretic PeptidesHeart Failure PharmacodynamicsHemodialysis PharmacokineticsHigh-performance Liquid Chromatography-mass SpectrometryHigh-sensitivity Troponin AssaysLeft Ventricular Ejection Fraction DeclineLiquid Chromatography-mass SpectrometryTandem Mass Spectrometry
BACKGROUND: Heart failure (HF) is one of the main comorbidities in patients receiving maintenance hemodialysis (HD). Sacubitril/valsartan (SAC/VAL) is widely used in HF patients with reduced ejection fraction (HFrEF) or HF mid-range ejection fraction (HFmrEF). However, the pharmacokinetic (PK) and pharmacodynamic properties of SAC/VAL in HD patients with HF remain uncertain. OBJECTIVES: This study aimed to analyze the efficacy and PK properties of SAC/VAL in HD patients with HFrEF or HFmrEF. METHODS: HD patients with HFrEF or HFmrEF were treated with SAC/VAL 50 or 100 mg twice a day (BID) and the concentrations of valsartan and LBQ657 (active metabolite of SAC) were determined by high-performance liquid chromatography-tandem mass spectrometry during HD and on the days between HD sessions (interval days). N-terminal-pro B-type natriuretic peptide and high-sensitivity troponin T were measured, and left ventricular ejection fraction (LVEF) was evaluated by echocardiography. RESULTS: The mean maximum plasma concentrations (Cmax) of LBQ657 and VAL on the interval days were 15.46 ± 6.01 and 2.57 ± 1.23 mg/L, respectively. Compared with previous values in patients with severe renal impairment and healthy volunteers, these levels both remained within the safe concentration ranges during treatment with SAC/VAL 100 mg BID. Moreover, SAC/VAL significantly improved LVEF in HD patients with HFrEF or HFmrEF (p < 0.05). CONCLUSIONS: HD did not remove the SAC metabolite LBQ657 or VAL in patients with HF. However, SAC/VAL 100 mg BID was safe and effective in patients undergoing HD.
15
John G.F. Cleland, Andrew J.S. Coats, Ewa A. Jankowska et al. · PubMed · 2021 · 19.5K citations
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
John J.V. McMurray, Milton Packer, Akshay S. Desai et al. · New England Journal of Medicine · 2014 · 6.8K citations · Full text
Medicine, Cardiology, Pharmacology +11